Free Trial
NASDAQ:XOMA

XOMA Royalty Q1 2025 Earnings Report

XOMA Royalty logo
$33.02 +0.96 (+2.99%)
As of 11:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

XOMA Royalty EPS Results

Actual EPS
$0.06
Consensus EPS
-$0.26
Beat/Miss
Beat by +$0.32
One Year Ago EPS
N/A

XOMA Royalty Revenue Results

Actual Revenue
$15.91 million
Expected Revenue
$6.75 million
Beat/Miss
Beat by +$9.16 million
YoY Revenue Growth
N/A

XOMA Royalty Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
7:30AM ET

Upcoming Earnings

XOMA Royalty's Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

XOMA Royalty Earnings Headlines

Former CIA Officer Reveals How Gold Saved His Life
This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained to stay alive when systems collapse. In Operation Gold Rush, Jason Hanson reveals how gold and silver saved his life—and how they could protect yours in the next crisis. You’ll learn how to hide gold like a covert operative, secure your 401(k) in physical assets, and prepare for grid failures, economic collapse, or worse.tc pixel
Leerink Partnrs Expects Reduced Earnings for XOMA Royalty
See More XOMA Royalty Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XOMA Royalty? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XOMA Royalty and other key companies, straight to your email.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

View XOMA Royalty Profile

More Earnings Resources from MarketBeat